ArticleFrontiers in public health2025
Clinical significance of cytokeratin 19 fragment in COVID-19 patients: a retrospective study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cytokeratin 19 fragment (CYFRA 21-1) is an important biomarker of lung cancer. There are clinical observations of elevated serum levels of lung cancer biomarkers in patients with viral pneumonia. However, the clinical significance of CYFRA 21-1 in coronavirus disease 2019 pneumonia has not been investigated. Methods: This retrospective study included 252 patients with community-acquired pneumonia (CAP) between December 1, 2022, and September 30, 2023. They were classified into three groups by clinical diagnosis and severity, namely mild non-COVID-19 CAP ( Results: CYFRA 21-1 levels progressively increased from mild non-COVID-19 CAP to mild COVID-19 and severe COVID-19. Lower lymphocyte and platelet counts, alongside elevated CYFRA 21-1 levels, were associated with COVID-19 pneumonia. Multivariate analysis identified CYFRA 21-1 as an independent diagnostic [diagnosis odds ratio (OR) = 2.369; 95% confidence interval (CI) = 1.638-3.605; Conclusion: CYFRA 21-1 may be a potential diagnostic and prognostic indicator of COVID-19 pneumonia. Prospective multicenter studies are needed to confirm its clinical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.